Literature DB >> 24907233

Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine.

Alessandro Serra1, Margaret M Skelly2, Jonathan B Jacobs2, Mark F Walker2, Jeffrey A Cohen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24907233      PMCID： PMC4117173          DOI： 10.1212/WNL.0000000000000567

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

1.  Modeling the mechanisms of Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis.

Authors:  Teresa C Frohman; Scott L Davis; Elliot M Frohman
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

2.  A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Authors:  Andrew D Goodman; Theodore R Brown; Keith R Edwards; Lauren B Krupp; Randall T Schapiro; Ron Cohen; Lawrence N Marinucci; Andrew R Blight
Journal:  Ann Neurol       Date:  2010-10       Impact factor: 10.422

3.  The role of the medial longitudinal fasciculus in horizontal gaze: tests of current hypotheses for saccade-vergence interactions.

Authors:  Athena L Chen; Stefano Ramat; Alessandro Serra; Susan A King; R John Leigh
Journal:  Exp Brain Res       Date:  2010-11-17       Impact factor: 1.972

4.  Using fast eye movements to study fatigue in multiple sclerosis.

Authors:  M Matta; R J Leigh; M Pugliatti; I Aiello; A Serra
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910
  4 in total
  6 in total

Review 1.  Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.

Authors:  Verena Isabell Leussink; Xavier Montalban; Hans-Peter Hartung
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

Review 2.  Vision and vision-related outcome measures in multiple sclerosis.

Authors:  Laura J Balcer; David H Miller; Stephen C Reingold; Jeffrey A Cohen
Journal:  Brain       Date:  2014-11-28       Impact factor: 13.501

Review 3.  Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment.

Authors:  Alessandro Serra; Clara G Chisari; Manuela Matta
Journal:  Front Neurol       Date:  2018-02-05       Impact factor: 4.003

4.  Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.

Authors:  Kawita M S Kanhai; Jenny A Nij Bijvank; Yorick L Wagenaar; Erica S Klaassen; KyoungSoo Lim; Sandrin C Bergheanu; Axel Petzold; Ajay Verma; Jacob Hesterman; Mike P Wattjes; Bernard M J Uitdehaag; Laurentius J van Rijn; Geert Jan Groeneveld
Journal:  CNS Neurosci Ther       Date:  2019-02-12       Impact factor: 5.243

5.  Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.

Authors:  J A Nij Bijvank; L J van Rijn; L J Balk; H S Tan; B M J Uitdehaag; A Petzold
Journal:  Neurology       Date:  2019-04-19       Impact factor: 9.910

6.  Vestibular rehabilitation in multiple sclerosis: study protocol for a randomised controlled trial and cost-effectiveness analysis comparing customised with booklet based vestibular rehabilitation for vestibulopathy and a 12 month observational cohort study of the symptom reduction and recurrence rate following treatment for benign paroxysmal positional vertigo.

Authors:  J Marsden; M Pavlou; R Dennett; A Gibbon; R Knight-Lozano; L Jeu; C Flavell; J Freeman; D E Bamiou; C Harris; A Hawton; E Goodwin; B Jones; S Creanor
Journal:  BMC Neurol       Date:  2020-11-27       Impact factor: 2.474
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.